Health Source (600380.SH): Leconchitazumab injection was included in the priority review and approval process

Zhitongcaijing · 4d ago

Zhitong Finance App News, Health Yuan (600380.SH) issued an announcement that the product of the company's holding subsidiary, Zhuhai Lizhudan Antibiotic Technology Co., Ltd. (abbreviation: Lizumab), was included in the publication list of varieties to be prioritized by the National Drug Administration Drug Evaluation Center on December 26, 2025; after the publicity period has expired, according to the disclosure of information on the China Drug Administration Drug Evaluation Center website, it has been included in the list of priority review varieties and officially entered the priority review and approval process for drug marketing licenses.

Proposed Indications (or Functional Indications): This product is suitable for adult patients with moderate to severe plaque psoriasis receiving systematic treatment or phototherapy.